Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria

[1] Hancock RE(1992)Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins J Antimicrob Chemother 29 1-6

[2] Bellido F(2005)Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update J Antimicrob Chemother 55 601-607

[3] Mouton JW(1995)Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 89-96

[4] Dudley MN(2001)Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters Clin Microbiol Infect 7 589-596

[5] Cars O(1998)Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1-10

[6] Derendorf H(1998)Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Antimicrob Agents Chemother 42 953-955

[7] Drusano GL(2001) by checkerboard and time-kill methodology Intensive Care Med 27 363-370

[8] Craig WA(2003)Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing Anesth Analg 97 1149-1154

[9] Jacobs MR(1984)Cefepime versus cefpirome: the importance of creatinine clearance Drug Metab Rev 15 265-292

[10] Craig WA(2001)Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model J Pharmacokinet Pharmacodyn 28 481-504

[1] Hancock RE(1992)Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins J Antimicrob Chemother 29 1-6

[2] Bellido F(2005)Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update J Antimicrob Chemother 55 601-607

[3] Mouton JW(1995)Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 89-96

[4] Dudley MN(2001)Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters Clin Microbiol Infect 7 589-596

[5] Cars O(1998)Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1-10

[6] Derendorf H(1998)Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Antimicrob Agents Chemother 42 953-955

[7] Drusano GL(2001) by checkerboard and time-kill methodology Intensive Care Med 27 363-370

[8] Craig WA(2003)Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing Anesth Analg 97 1149-1154

[9] Jacobs MR(1984)Cefepime versus cefpirome: the importance of creatinine clearance Drug Metab Rev 15 265-292

[10] Craig WA(2001)Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model J Pharmacokinet Pharmacodyn 28 481-504